Department of Metabolism & Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, Hunan, 410011, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, Hunan, 410011, People's Republic of China.
Rev Endocr Metab Disord. 2020 Dec;21(4):645-655. doi: 10.1007/s11154-020-09544-x.
Paget's disease of bone (PDB) is a metabolic bone disease with distinct geographical and ethnic differences in its pathogenesis. In this study, we aimed to retrospectively analyze the clinical features and the status of diagnosis and treatment of PDB in mainland China to improve the clinician's understanding of this disease. For this purpose, we conducted a systematic review of 118 articles, including a total of 332 patients with PDB. The results showed that the onset age of PDB in mainland China was 46-60 years. The number of male patients in most age groups was slightly higher than that of female patients, but there was no statistical difference (p > 0.05). The gender ratio (male to female) of PDB in mainland China was significantly different from that in Japan (p < 0.05), but not from that in the USA (p > 0.05). The clinical manifestations of PDB patients in mainland China mainly included ostealgia, bone malformation, hearing loss, and fracture, and bisphosphonate was used as the main treatment drug. These findings were similar to those in Japan, UK, and USA. Total alkaline phosphatase (TALP) level was elevated in about 89.7% of patients, and no correlation between TALP level and ostealgia was observed (p > 0.05). In addition, no difference in TALP level between males and females in each group was observed (p > 0.05).
佩吉特病(Paget's disease of bone,PDB)是一种代谢性骨病,其发病机制在地理和种族上存在明显差异。本研究旨在回顾性分析中国大陆 PDB 的临床特征、诊断和治疗现状,以提高临床医生对该病的认识。为此,我们对 118 篇文章进行了系统评价,共纳入 332 例 PDB 患者。结果显示,中国大陆 PDB 的发病年龄为 46-60 岁。大多数年龄组男性患者略多于女性,但差异无统计学意义(p>0.05)。中国大陆 PDB 的性别比(男:女)与日本明显不同(p<0.05),但与美国无差异(p>0.05)。中国大陆 PDB 患者的临床表现主要包括骨痛、骨畸形、听力损失和骨折,双膦酸盐是主要的治疗药物。这些发现与日本、英国和美国的研究结果相似。约 89.7%的患者总碱性磷酸酶(total alkaline phosphatase,TALP)水平升高,但 TALP 水平与骨痛之间无相关性(p>0.05)。此外,各年龄组男女 TALP 水平无差异(p>0.05)。